CyBio AG
CyBio AG english
Sales and EBIT Below Prior-Year Level – Trend reversal not expected until 2002
Ad-hoc-announcement transmitted by DGAP.
The issuer is solely responsible for the content of this announcement.
——————————————————————————–
Jena, November 20, 2001: In the first nine months of fiscal 2001, CyBio AG, of
Jena, Germany (Neuer Markt: 541230), recorded sales of EUR 9.68 million (US-
GAAP). In comparison with the same period in the previous year (EUR 15.61
million), this represents a decline of about 38 percent. Earnings before
interest and taxes (EBIT) for the first nine months ending September 30, 2001
amounted to EUR -12.13 million (comparable period of the prior year: EUR -3.31
million). EBIT is characterized by precautionary measures resulting from weak
sales and a disproportionate development of inventories. It also includes non-
cash expenses from the stock option program in the amount of EUR 2.44 million
(comparable period of the prior year: EUR 3.31 million).
The Jena-based biotech company does not anticipate a trend reversal in sales
before year-end. CyBio AG expects that the last three months of the year will
develop at roughly the same rate as the preceding quarters. The same also
applies to projected earnings since the measures for cost savings introduced in
early October, above all including the elimination of 28 jobs, will not fully
come to bear until January 2002.
A positive indicator in the reporting period was the sale of another complete
CyBi(TM) screen machine lab system, which means that the sale of five complete
systems projected for 2001 should be fulfilled. In addition, CyBio AG has come a
decisive step further in research and development in implementing its
biocybernetic concept. CyBio AG plans to introduce the first practical results
of the recently realized Internet-capable telemonitoring for CyBio lab systems
at this year’s MEDICA trade fair in Düsseldorf (November 21 to 24). This
technology makes it possible to monitor complex applications anytime from
anywhere in the world.
Contact:
CyBio AG / Cornelia Todt IR/PR
Göschwitzer Str. 40, 07745 Jena
Tel. +49 3641 351425, Fax +49 3641 351360
E-Mail: cornelia.todt@cybio-ag.com
end of ad-hoc-announcement (c)DGAP 20.11.2001
——————————————————————————–
WKN: 541230; Index:
Listed: Neuer Markt in Frankfurt; Freiverkehr in Berlin, Bremen, Düsseldorf,
Hamburg, Hannover, München und Stuttgart
200757 Nov 01
Latest News
Latest Reports
Upcoming Events
No Events found
Webcasts
No Webcasts found